Exclusive Financial Advisor to TRiCares SAS on its Investment from a Strategic Investor
Oppenheimer & Co. Inc. acted as Exclusive Financial Advisor to TRiCares SAS on its $50 million investment from a strategic investor
TRiCares SAS (“TRiCares”) a privately-held pioneer in the field of minimally-invasive treatment of tricuspid regurgitation announced that it has received a $50 million Series D investment from an undisclosed strategic investor. The proceeds from this financing will primarily be used to support the company through upcoming US and EU clinical milestones for its transfemoral tricuspid heart valve replacement (TTVR) system, Topaz.
TRiCares is a clinical-stage developer of transcatheter minimally-invasive technologies for tricuspid regurgitation. Its lead product, Topaz, is a TTVR system designed to replace the native tricuspid heart valve via minimally invasive transfemoral delivery without prior surgical removal of the diseased native tricuspid valve.
This notice is provided for informational purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
2024 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 6833570.1